MEET EUROPE AT BIO 2017

The EU pavilion: your one-stop shop for information on research and innovation funding, regulatory issues, and partnering opportunities in the European Union.



European Commission,
Directorate-General for Research & Innovation

The European Commission is present at BIO International Convention through its Directorate–General for Research and Innovation, which is in charge of defining and implementing European research and innovation policies. These policies are supported by Horizon 2020, the largest and most ambitious framework program for research and innovation undertaken by the European Union ever (worth €80 billion), and among the largest in the world. Horizon 2020 is open for business and offers considerable support for researchers operating in the life science and healthcare research cycle, including for the digital and personalised transformation of health and care. Horizon 2020 offers a unique range of opportunities, from grants to individuals for performing blue sky research, to collaborative research with industry and support to research infrastructures. It provides a unique frame for international cooperation and encourages intercontinental joint efforts such as for research on rare diseases or on public health emergencies. User friendly for companies looking for high growth – with disruptive ideas – offering them funding and business support, Horizon 2020 provides tailor-made instruments for the varying needs of health research companies and SMEs. In recognition of the opening of the US National Institutes of Health's programmes to European researchers, any legal entity established in the United States of America is eligible to receive Union funding to support its participation in projects supported under the Health, Demographic Change and Wellbeing Societal Challenge.

@EU_H2020
@EUScienceInnov
#H2020

www.ec.europa.eu/research/health

The application process for Horizon 2020 is entirely online:

https://ec.europa.eu/programmes/horizon2020

Find us in the BIO education program

FAST TRACK TO ORPHAN DRUGS
Tuesday June 20 · 4:15 PM–5:15 PM · Room 3

JOIN OUR MINI-SESSIONS AT THE EU PAVILION - BOOTH 5737

European research funding opportunities – what's in it for you?

June 20, 10:45 AM–11:15 AM
June 20, 2:00 PM–2:30 PM
June 21, 12:00 PM–12:30 PM
June 22, 10:45 AM–11:15 AM
June 22, 2:00 PM–2:30 PM

EU research to assist advanced therapies

June 20, 2:30 PM–3:00 PM
June 21, 3:30 PM–4:00 PM

Transatlantic expansion: how to establish your US biotech business in Europe or vice versa in the USA

June 21, 2:00 PM–2:30 PM

innovative medicines initiative

@IMI_JU

Download our latest highlights from:

www.imi.europa.eu

Innovative Medicines Initiative (IMI)

The Innovative Medicines Initiative (IMI) is Europe's largest public-private initiative with a total budget of €5.3 billion for the period 2008-2024. It is a partnership between the European Union and the pharmaceutical industry association EFPIA.

IMI's goal is to improve health by speeding up the development of, and patient access to, innovative medicines, particularly in areas where there is an unmet medical or social need.

IMI funds collaborative research projects and builds networks of key players involved in healthcare research, including universities and research centers, the pharmaceutical and other industries, small and medium-sized enterprises (SMEs), patient organizations, and medicines regulators.

As true enablers of breakthroughs and innovation, biotech industries and SMEs can play a unique role to help IMI translate science into technology applications, in an unprecendented partnership for faster and better cures. In the latest phase of its program, IMI has furthered its partnership to the digital health, diagnostics, imaging, and animal health industries.

Together, we are finding innovative health solutions to the most pressing medical burdens of our times.

Find us in the BIO education program

DETECT, PREDICT, PREVENT:
USING DIGITAL TECHNOLOGIES TO TACKLE BRAIN DISORDERS
Thursday June 22 · 11:30 AM–12:45 PM · Room 6EF

JOIN OUR MINI-SESSIONS AT THE EU PAVILION - BOOTH 5737

The Innovative Medicines Initiative (IMI): Meet Europe's partnership for health
June 20, 11:30 AM–12:00 PM
June 21, 11:30 AM–12:00 PM

EUROPEAN MEDICINES AGENCY
SCIENCE MEDICINES HEALTH

@EMA_News

www.ema.europa.eu

European Medicines Agency (EMA)

The European Medicines Agency (EMA) is responsible for the scientific evaluation, supervision and safety monitoring of medicines for human and veterinary use in the European Union (EU).

As an enabler of innovation, EMA encourages research and development of new medicines. Scientific guidance and scientific advice from EMA help medicines developers translate progress in medical science into medicines that bring real public health benefits for EU citizens. Patients with rare diseases benefit from a program that promotes the development of so-called orphan medicines. EMA guides and stimulates the development of medicines for children through its opinions on companies' pediatric investigation plans (PIPs).

In March 2016 EMA launched the PRIME (PRIority Medicines) scheme, to support the development of promising, innovative medicines that have the potential to address patients' unmet needs. Through PRIME, the Agency helps medicine developers to optimize the generation of robust data on a medicine's benefits and risks and to enable accelerated assessment of medicines applications.

EMA promotes innovation and development by micro, small and medium-sized enterprises (SMEs) of new medicines for human and veterinary use, providing regulatory, financial and administrative assistance through a dedicated SME office that can address the specific needs of small pharmaceutical companies.

EMA has had an active international role since its creation in 1995. Relations with regulators from the USA, Canada, Japan, Australia and Switzerland and with WHO have been formalized through Confidentiality Arrangements (CAs). EMA and the US FDA have established some 18 platforms, involving also other regulators, to cooperate in different therapeutic areas, types of activities and biologicals, including biosimilars. EMA and FDA offer sponsors the opportunity to engage both agencies at the same time through parallel scientific advice on questions at any stage of the development of medicines. The goal is to ensure convergence in requirements for global clinical studies and global development.

In 2017, the EU and the US have signed a mutual recognition agreement (MRA) on good manufacturing practice (GMP) inspections to make better use of inspection capacity and reduce duplication.

JOIN OUR MINI-SESSION AT THE EU PAVILION - BOOTH 5737

European Medicines Agency: Support to SMEs
June 21, 10:45 AM – 11:15 AM

Contact us at BIO:

European Commission, Directorate-General for Research & Innovation

Arnd Hoeveler
Head of Unit, Innovative tools, technologies and concepts in health research
arnd.hoeveler@ec.europa.eu

Philippe Cupers
Deputy Head of Unit, Health Strategy
philippe.cupers@ec.europa.eu

Elmar Nimmesgern
Deputy Head of Unit, Innovative and Personalised Medicine
elmar.nimmesgern@ec.europa.eu

Dan Nacu–Manole
Information and Communication Officer, Health Strategy
dan.nacu-manole@ec.europa.eu

Hilde Somers
Financial Officer, Health Strategy
hilde.somers@ec.europa.eu

Innovative Medicines Initiative (IMI)

Pierre Meulien
Executive Director
pierre.meulien@imi.europa.eu

Magali Poinot
Advisor to the Executive Director
magali.poinot@imi.europa.eu

Alessandra Paccamiccio
Communications & Events Officer
alessandra.paccamiccio@imi.europa.eu

European Medicines Agency (EMA)

Sabine Haubenreisser
European Medicines Agency Liaison Official at the FDA
sabine.Haubenreisser@ema.europa.eu

Print FS-01-17-544-EN-D ISBN: 978-92-95207-05-9 doi: 10.2879/962891
PDF FS-01-17-544-EN-N ISBN: 978-92-95207-04-2 doi: 10.2879/84261

MEET US AT THE EU PAVILION

STAND 5737